文献速递MDS 与骨髓增殖性肿瘤血栓与止血

骨髓增殖性肿瘤血栓起源的临床见解

Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.
PubMed 文献 · Blood · 2021-01-01

该综述重新评估了费城染色体阴性骨髓增殖性肿瘤(MPN)包括真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的血栓负担。文章回顾了克隆性造血、JAK2V617F负荷、炎症与血栓之间的临床关联,并探讨了新型一级和二级血栓预防策略。

要点

  • MPN患者血栓发生率高,是疾病主要临床负担之一。
  • 克隆性造血、JAK2V617F负荷与炎症可能共同促进血栓形成。
  • 需探索新型一级和二级血栓预防策略以改善MPN患者预后。

核心结论

  • MPN患者具有高血栓风险,克隆性造血、JAK2V617F负荷和炎症与血栓形成相关,需关注新型预防策略。

研究设计与样本

  • 综述,重新评估MPN中血栓的临床负担并回顾相关临床关联。

主要发现

  • MPN以信号转导通路激活突变为特征,临床表现为血小板、红细胞和中性粒细胞过度产生及高血管事件率。
  • 克隆性造血、JAK2V617F负荷和炎症与血栓形成存在临床关联。

临床怎么用

  • 临床应重视MPN患者的血栓风险评估,并考虑新型一级和二级预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are hematopoietic stem cell disorders that are defined by activating mutations in signal transduction pathways and are characterized clinically by the overproduction of platelets, red blood cells, and neutrophils, significant burden of disease-specific symptoms, and high rates of vascular events. The focus of this review is to critically reevaluate the clinical burden of thrombosis in MPNs, to review the clinical associations among clonal hematopoiesis, JAK2V617F burden, inflammation, and thrombosis, and to provide insights into novel primary and secondary thrombosis-prevention strategies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Moliterno AR, Ginzburg YZ, Hoffman R, et al. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood. 2021. PMID: 33237986. doi:10.1182/blood.2020008043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。